Summary: Learn about the major achievements in the gene therapy market in 2023, with a focus on reliable manufacturing processes and strategies to enhance predictability while reducing waste in gene therapy manufacturing.

Summary: Learn about the major achievements in the gene therapy market in 2023, with a focus on reliable manufacturing processes and strategies to enhance predictability while reducing waste in gene therapy manufacturing.

This webinar explored the challenges of cell therapy manufacturing and introduced Catalent's UpTempo CAR-T Platform process as a solution.

Summary: In a recent presentation during the 2024 JP Morgan Healthcare Conference, Catalent’s Group President of Biologics Dave McErlane addresses the latest market drivers for Biologics and Sterile Injectables.

Learn about pluripotent stem cells and how they're being explored as an exciting alternative gene therapy technology with the potential to transform the field of regenerative medicine.

In recent years, the field of gene therapy has witnessed remarkable achievements and advancements. These breakthroughs have brought us even closer to unleashing the full potential of gene therapies. Catalent gene therapy experts discuss all aspects of gene therapy commercialization in depth.

A poster presentation of a GMP manufacturing process for the creation of human iPSC for use in allogeneic cell therapy applications.

A poster presentation of the UpTempo CAR-T Manufacturing Platform.

In this webinar, experts discuss the current state-of-the-art for iPSC generation and differentiation. The presentation will also highlight the development of advanced CGMP-compatible protocols for converting these cells into several cell types of therapeutic relevance, including retinal pigment epithelium (RPE), mesenchymal stem cells (MSCs), cardiomyocytes (CMs), and immune natural killer (NK) cells.

Catalent’s Maria Lopez, General Manager of US Cell Therapy discusses the current state of the cell therapy market and the ways Catalent is working to overcome some of these challenges. Based on an interview conducted by, and published in, BioBuzz.